Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Quidel

Thumbnail
January 29, 2021

Ortho Clinical takes a haircut

Discount pricing and poor first day defies the recent trend for floating device makers.

Thumbnail
December 16, 2020

A new setting for antigen testing

It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.

Article image
Vantage logo
December 01, 2020

The promise and the perils of antigen testing

A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.

Article image
Vantage logo
October 26, 2020

Balancing the accuracy and cost of antigen testing

Antigen tests for Covid-19 can be useful if used in the right settings, but those settings are expensive.

Article image
Vantage logo
October 12, 2020

Two more antigen tests get US nod

Article image
Vantage logo
September 02, 2020

Testing demand could mitigate Roche’s second place

Article image
Vantage logo
August 27, 2020

Abbott rides to the rescue with $5 Covid-19 test

The BinaxNow antigen test is fast and acceptably accurate – but above all, cheap.

Article image
Vantage logo
July 08, 2020

Smaller device makers put in a muted performance

Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.

Article image
Vantage logo
May 11, 2020

Quidel wins the Covid-19 antigen test race

Antigen tests are faster and cheaper than viral RNA assays, but are notably less accurate.

Article image
Vantage logo
March 20, 2020

Genmark adds $100m in value on Covid-19 test authorisation

Article image
Vantage logo
August 02, 2018

Medtechs prioritise efficiency when it comes to hiring

Big cap medtech is hiring, largely thanks to organic growth.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.